The Use of Low Molecular Weight Heparin in Hemodiafiltration

Condition(s) targeted: Chronic Kidney Disease

Intervention: At start of the session, at the inlet line (Procedure); 5 minutes after the start of the session, at the inlet line (Procedure); At the start of the session, at the outlet line (Procedure)

Phase: Phase 4

Status: Completed

Sponsored by: University Hospital, Ghent

Official(s) and/or principal investigator(s):
Annemieke Dhondt, MD, PhD, Principal Investigator, Affiliation: University Hospital, Ghent

Low molecular weight heparin (LMWH) is injected in the dialysis circuit at the start of the session. In the present study we compare 3 different methods of injection of LMWH: parameters of dialysis efficiency and clotting are measured. The study lasts 3 sessions for each patient.

Official title: The Use of Low Molecular Weight Heparin in Hemodiafiltration

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Anti-Xa activity at the end of the session

Secondary outcome:

Anti-Xa activity during the session

ETP during the session

Reduction ratio of urea

Reduction ratio of beta2microglobulin

Visual inspection of membrane and circuit

pressure measurements along the circuit

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- chronic kidney disease stade V treated with hemodiafiltration

- age >18 year

- Hematocrit > 30%

Exclusion Criteria:

- treatment with vitamin K antagonists

- treatment with other anti-coagulants or heparin besides the heparin used during

dialysis

- active bleeding, infection or malignancy

- heparin associated allergy

- hepatic failure

- trombocytopenia < 120. 000/µl

University Hospital Ghent, Ghent 9000, Belgium

Website of the University Hospital Ghent

Starting date: September 2008
Last updated: May 13, 2015